Biomimetics (bī-ō-mə-‘me-tiks): The development of synthetic materials that mimic the structure and function of naturally occurring substances for the purpose of solving complex human problems.

BioMimetic Laboratories translates natural anti-aging solutions into powerful skincare products through biomimetics. Our mission is to maximize and optimize the use of biomimetics in skincare, using safe and sustainably-produced molecules, inspired by mother nature. Founded on close R&D partnerships with academic and pharmaceutical discovery laboratories, BioMimetic Laboratories selects lead molecules from our partners’ libraries and refines the molecular properties of these actives to create potent, patented anti-aging cosmetic products. Building upon this innovative model of collaboration between discovery and cosmetic scientists, BioMimetic Laboratories will lead the industry in transforming the best that nature has to offer into powerful skincare solutions. 



Our premiere launch is a topical concentrate that relaxes facial muscles, without blocking movement, and instantly smooths skin. This concentrate combines the latest pharmaceutical technology with the formulation expertise of SBV, creating a best-in-class topical alternative to surgical procedures. 

Our pioneering product exemplifies the power of biomimetics. The basis of our formulation is a naturally occurring cone snail neurotoxin discovered by the Swiss biotech company Atheris Laboratories and produced synthetically by their cosmetic partner Activen. While the power of neurotoxins in wrinkle reduction is well documented, actualizing this potential into efficacious topical formulations is highly challenging.  Our scientists collaborated with Activen researchers to modify the XEP-018 core resulting in a novel peptide with greater potency, ideally suited to achieve superior results in a topical formulation and exclusively available to BioMimetic Laboratories. Product is currently undergoing final R&D and preliminary market and clinical testing, with a product launch scheduled for the first half of 2015. 

R&D PARTNER: XEP-018, the synthetic mimetic biopeptide that forms the core of the actives in our product is patented by Atheris Laboratoriesa Swiss biotechnology company. The advanced next generation version(s) of the biopeptide are the result of joint R&D efforts between Skyler and Atheris Laboratories and provide our product  with unique and powerful advantages over existing competition.

MARKETING PARTNER: The Conversation Agency is an award-winning, global marketing and advertising agency that prides itself on its “new traditional” approach. Frank O'Brien, Conversation's founder and CEO acts as the Chief Marketing Officer for the company and the agency is our marketing department.  The team is made up of a diverse group of people – with a diverse range of skill-sets – providing grounded expertise in today’s evolving marketplace.  The agency is also a founding shareholder in the company.




PACKAGING DESIGN PARTNER: Big Sky is our primary packaging design partner. They provide custom packaging and promotional products for the fragrance, beauty, home, hotel amenity, wine and spirit industries. Big Sky has worked with some of the biggest names in the beauty business.


CONTRACT MANUFACTURING PARTNER: The Company has narrowed our contract manufacturer selection to two finalists; both are highly regarded contract manufacturers for large, global cosmetic companies and meet our stringent quality stanadards.  A final decision on the manufacturer will be at the end of the development phase.


Amy Bevacqua_bw_6 by 6.jpg

Amy Bevacqua: Ms. Bevacqua is currently an Associate General Counsel at New York University focusing on the endowment portfolio and financings. Previously she was Vice President and Deputy General Counsel of AEA Investors for nine years, where she was responsible for a variety of fund, transaction and portfolio company management activities, including corporate governance. She started her legal career as an associate with Shearman & Sterling LLP, serving in its New York, London and Paris offices. Amy received her J.D. with honors from Boston University School of Law, where she was Executive Editor of the International Law Review, a Paul J. Liaco Scholar and a G. Joseph Tauro Scholar. She received her B.A. with honors from Barnard College, Columbia University.   Ms. Bevacqua is the lead independent director on the board. 

Julius "Jules" Zecchino: Mr. Jules Zecchino, is the founder, key shareholder and Chairman of the Board for BioMimetic Laboratories as well as the founder and Chief Scientific Officer of Skyler Brand Ventures.  He is the former Head of Skin Care R&D at Estée Lauder, where for over 20 years he was responsible for the development of the company's top performing products in their multi-billion dollar segments. His team at Lauder also won the prestigious Marie Claire Prix d'Excellence (the Beauty Industry's Oscar) an unprecedented five years in a row. He is an active member of the International Academy of Cosmetic Dermatology, Society of Investigative Dermatology, CEW and SCC.

Ravi Suria: Mr. Suria represents the lead and founding investor in BioMimetic Laboratories.  He is the founder/CIO at Valmiki Capital Management LP and  Co-founder and Executive Chairman at BuildForward Capital LLC.  He was previously a portfolio manager at Moore Capital managing a global equities portfolio.  Prior to Moore Capital he was Managing Director at Duquesne Capital Management.  He is a Trustee for Bronx Prep Charter School and the Bronx Defenders.  Mr. Suria received his  B.E. from Annamalai University (1991) and his MBA from Tulane University (1995).

Hemali Dassani: Ms. Dassani is an outside independent director on the board and is the Director of Investor Relations at Castle Harlan, focusing on client service, communication, relationship management, and capital-raising. Previously, Ms. Dassani was a Managing Director with Old City Investment Partners, a multi-family office dedicated to finding high quality investments for the firm's clientele of family office investors. Ms. Dassani has a history of working with alternative investment firms, especially Private Equity funds, raising capital globally. She has an M.B.A. from the Harvard Business School and a B.Sc. in Industrial Engineering from Northwestern University. Ms. Dassani is President of the Harvard Business School Club of Greater New York, and sits on the Board of Governors for the Harvard Business School Real Estate Alumni Association and the Steering Committee for the Harvard Business School Alumni Angels Association.